<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00499122</url>
  </required_header>
  <id_info>
    <org_study_id>20071167</org_study_id>
    <secondary_id>MUSC-101072</secondary_id>
    <secondary_id>MUSC-HR-17111</secondary_id>
    <nct_id>NCT00499122</nct_id>
  </id_info>
  <brief_title>NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer</brief_title>
  <official_title>Phase II Study of Neoadjuvant Treatment With NOV-002 in Combination With Doxorubicin and Cyclophosphamide Followed by Docetaxel in Patients With Stages IIB-IIIC Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Oxidized glutathione (NOV-002) may stimulate the immune system in different ways
      and stop tumor cells from growing. Drugs used in chemotherapy, such as doxorubicin,
      cyclophosphamide, and docetaxel, work in different ways to stop the growth of tumor cells,
      either by killing the cells or by stopping them from dividing. Giving more than one drug
      (combination chemotherapy) may kill more tumor cells. Giving NOV-002 together with
      chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue
      that needs to be removed.

      PURPOSE: This phase II trial is studying how well giving oxidized glutathione (NOV-002)
      together with doxorubicin and cyclophosphamide followed by docetaxel works in treating women
      with newly diagnosed stage II or stage III breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE: This is a multicenter study.

      Patients receive oxidized glutathione (NOV-002) IV twice on day -1 of course 1 and once on
      day 1 of courses 2-8. Patients receive NOV-002 subcutaneously once daily on days 2-21 of
      courses 1-8. Patients also receive chemotherapy comprising doxorubicin hydrochloride IV and
      cyclophosphamide IV on day 1 of courses 1-4 followed by docetaxel IV on day 1 of courses 5-8.
      Treatment repeats every 21 days in the absence of disease progression or unacceptable
      toxicity.

      Patients undergo definitive surgery 3-6 weeks after completion of neoadjuvant therapy.

      Blood samples are obtained at baseline and periodically during study to measure serum and
      plasma protein glutathionlylation. Additional blood samples are collected from some patients
      for immunological correlative studies.

      After completion of study therapy, patients are followed at 30 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 4, 2007</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Pathologic Complete Response in the Affected Breast After Protocol Therapy</measure>
    <time_frame>About 7 months</time_frame>
    <description>The primary objective of this study is to define the rate of pathologic complete response rate (pCR) in the affected breast after the preoperative administration of NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with stage IIB-IIIC breast cancer. Pathologic complete response (pCR) is defined according to Hankoop et al [41] as either: the absence of any histological evidence of invasive breast cancer cells in the tissue specimen removed from the breast or the presence of invasive tumor equal to or less than 10mm after preoperative treatment, determined at definitive breast surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Definition of the Safety Profiles of Protocol Therapy</measure>
    <time_frame>Up to 30 days Post-Last Dose of Protocol Therapy, About 7 months</time_frame>
    <description>Definition of the safety profiles of protocol therapy in study participants as shown by the number of study participants experiencing adverse events or other toxicity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation Between Myeloid Derived Suppressor Cell (MDSC) Levels and Pathologic Complete Response (pCR) and Non-Responders</measure>
    <time_frame>Baseline, Day 1 of Cycles 1 through 8, about 7 months</time_frame>
    <description>The investigators hypothesized that patients with favorable responses, i.e. pCR, are more likely to have significantly lower levels of MDSCs than non-responders. MDSC levels will be measured at baseline and on day 1 of each treatment cycle, cycles 1 through 8.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>NOV-002 and Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NOV-002:
Cycle 1, Day -1 only: 60 mg intravenously (IV) x 2, 3 hours (+/- 30 minutes) apart
Cycles 1 - 8, Day 1: 60 mg IV, 1 hour (+/- 30 minutes) prior to chemotherapy administration
Cycle 1 - 8, Days 2 - 21: 60 mg subcutaneous injections
Cyclophosphamide: 600 mg/m2 IV, Cycles 1 - 4, Day 1
Doxorubicin: 60 mg/m2 IV, Cycles 1 - 4, Day 1
Docetaxel: 100 mg/m2 IV, Cycles 5 - 8, Day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <arm_group_label>NOV-002 and Chemotherapy</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <arm_group_label>NOV-002 and Chemotherapy</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <arm_group_label>NOV-002 and Chemotherapy</arm_group_label>
    <other_name>Adriamycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NOV 002</intervention_name>
    <arm_group_label>NOV-002 and Chemotherapy</arm_group_label>
    <other_name>Oxidized glutathione</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females age 18 years or older.

          -  The ability to provide written informed consent prior to study specific screening
             procedures, with the understanding that the patient has the right to withdraw from the
             study at any time.

          -  Histologically confirmed infiltrating (invasive) breast cancer by core needle biopsy,
             with no evidence of metastatic disease except to the ipsilateral axillary lymph nodes.

          -  Clinical stage IIB - IIIC (T2-4, N0 or N1, M0 or - any T, N1-3, M0) breast cancer. The
             primary tumor must be greater than or equal to 2 cm (T2-4) or with pathologically
             proven axillary nodal involvement (N1-3).

          -  Patients with inflammatory breast cancer (T4) are permitted into the study.

          -  Clinically palpable tumor that meets the criteria of RECIST for palpable measurable
             disease. The primary tumor must be greater than or equal to 2 cm (T2-4) or with
             pathologically proven axillary nodal involvement (N1-3). Bilateral synchronic breast
             cancers are allowed but one of the primary tumors should be selected as the target
             tumor.

          -  Primary tumor may be estrogen or progesterone receptor negative or positive, and human
             epidermal growth factor receptor 2 (HER-2/neu) negative as determined by either
             Fluorescent In Situ Hybridization (FISH) or 0-2+ staining by immunohistochemistry
             (IHC) (Hercept™).

          -  Normal cardiac ejection fraction (EF ≥ 50%) as determined by screening multigated
             acquisition scan (MUGA) or echocardiogram.

          -  No prior history of myocardial infarction, congestive heart failure, symptomatic
             coronary artery disease, or cardiac arrhythmias.

          -  Patients must be ambulatory with Eastern Cooperative Oncology Group (ECOG) Performance
             Status of 0-1.

          -  The patient or her caregiver must be able to self administer daily subcutaneous
             injections.

          -  Life expectancy greater than 6 months.

        Exclusion Criteria:

          -  Prior therapy of any modality for the treatment of breast cancer

          -  Any prior therapy with an anthracycline or a taxane for any other indication

          -  HER-2 positive breast cancer defined as either gene amplification by Fluorescent In
             Situ Hybridization (FISH) or 3+ staining by IHC (Hercept™).

          -  Women who have a positive pregnancy test, no pregnancy test available, who are
             pregnant or who are lactating.

          -  Women of childbearing potential must agree to use a reliable and appropriate
             contraceptive method, which could include a double barrier method (condom plus
             diaphragm), an intrauterine device or oral contraceptives. Women with ER or PR
             positive breast cancer, should not, however, use oral contraceptives as a method of
             contraception. Postmenopausal women must have been amenorrheic for at least 12 months
             to be considered of non-childbearing potential.

          -  Women with breast cancer that do not have palpable breast tumors at screening.

          -  History of another malignancy within the last 5 years except curatively treated basal
             cell carcinoma of the skin or cervical intraepithelial neoplasia.

          -  Clinically significant (i.e. active) cardiac disease (NYHA Grade II or greater
             congestive heart failure, symptomatic coronary artery disease, unstable angina, and
             cardiac arrhythmia not well-controlled with medication), myocardial infarction within
             the last 6 months prior to study start, or screening ejection fraction of &lt; 50%.

          -  Any of the following abnormal laboratory values:

               -  Absolute neutrophil count &lt; 1.5 x 109/L

               -  Platelet count &lt; 100 x 109/L

               -  Serum bilirubin &gt; 1.5 x upper limit of normal (ULN)

               -  Serum alanine transaminase (ALT), aspartate transaminase (AST) &gt; 2.5 x ULN

               -  Serum creatinine &gt; 2.0 mg/dL or 177mmol/L or calculated creatinine clearance by
                  the method of Cockcroft and Gault &lt; 50mL/min).

          -  Any severe or poorly controlled systemic disease (e.g., hypertension; clinically
             significant cardiovascular, pulmonary, or metabolic disease, disorders of
             wound-healing, ulcer or bone fracture).

          -  Patients who have received any investigational treatment within 4 weeks of study
             start.

          -  Known infection with HIV, Hepatitis B virus (HBV), or Hepatitis C virus (HCV).

          -  Known hypersensitivity to any of the components of NOV-002 or to any of the study
             drugs.

          -  Patients assessed by the investigator to be unable or unwilling to comply with the
             requirements of the protocol.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keisuke Shirai, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alberto Montero, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hollings Cancer Center at Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Montero AJ, Diaz-Montero CM, Deutsch YE, Hurley J, Koniaris LG, Rumboldt T, Yasir S, Jorda M, Garret-Mayer E, Avisar E, Slingerland J, Silva O, Welsh C, Schuhwerk K, Seo P, Pegram MD, Glück S. Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer. Breast Cancer Res Treat. 2012 Feb;132(1):215-23. doi: 10.1007/s10549-011-1889-0. Epub 2011 Dec 3.</citation>
    <PMID>22138748</PMID>
  </results_reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2007</study_first_submitted>
  <study_first_submitted_qc>July 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2007</study_first_posted>
  <results_first_submitted>January 18, 2013</results_first_submitted>
  <results_first_submitted_qc>February 20, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 29, 2013</results_first_posted>
  <last_update_submitted>December 6, 2017</last_update_submitted>
  <last_update_submitted_qc>December 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>inflammatory breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>NOV-002 and Chemotherapy</title>
          <description>NOV-002:
Cycle 1, Day -1 only: 60 mg intravenously (IV) x 2, 3 hours (+/- 30 minutes) apart
Cycles 1 - 8, Day 1: 60 mg IV, 1 hour (+/- 30 minutes) prior to chemotherapy administration
Cycle 1 - 8, Days 2 - 21: 60 mg subcutaneous injections
Cyclophosphamide: 600 mg/m2 IV, Cycles 1 - 4, Day 1
Doxorubicin: 60 mg/m2 IV, Cycles 1 - 4, Day 1
Docetaxel: 100 mg/m2 IV, Cycles 5 - 8, Day 1</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>NOV-002 and Chemotherapy</title>
          <description>NOV-002:
Cycle 1, Day -1 only: 60 mg intravenously (IV) x 2, 3 hours (+/- 30 minutes) apart
Cycles 1 - 8, Day 1: 60 mg IV, 1 hour (+/- 30 minutes) prior to chemotherapy administration
Cycle 1 - 8, Days 2 - 21: 60 mg subcutaneous injections
Cyclophosphamide: 600 mg/m2 IV, Cycles 1 - 4, Day 1
Doxorubicin: 60 mg/m2 IV, Cycles 1 - 4, Day 1
Docetaxel: 100 mg/m2 IV, Cycles 5 - 8, Day 1</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Pathologic Complete Response in the Affected Breast After Protocol Therapy</title>
        <description>The primary objective of this study is to define the rate of pathologic complete response rate (pCR) in the affected breast after the preoperative administration of NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with stage IIB-IIIC breast cancer. Pathologic complete response (pCR) is defined according to Hankoop et al [41] as either: the absence of any histological evidence of invasive breast cancer cells in the tissue specimen removed from the breast or the presence of invasive tumor equal to or less than 10mm after preoperative treatment, determined at definitive breast surgery.</description>
        <time_frame>About 7 months</time_frame>
        <population>Assessable tumors from study participants who had received at least one cycle of protocol therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>NOV-002 and Chemotherapy</title>
            <description>NOV-002:
Cycle 1, Day -1 only: 60 mg intravenously (IV) x 2, 3 hours (+/- 30 minutes) apart
Cycles 1 - 8, Day 1: 60 mg IV, 1 hour (+/- 30 minutes) prior to chemotherapy administration
Cycle 1 - 8, Days 2 - 21: 60 mg subcutaneous injections
Cyclophosphamide: 600 mg/m2 IV, Cycles 1 - 4, Day 1
Doxorubicin: 60 mg/m2 IV, Cycles 1 - 4, Day 1
Docetaxel: 100 mg/m2 IV, Cycles 5 - 8, Day 1</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Pathologic Complete Response in the Affected Breast After Protocol Therapy</title>
          <description>The primary objective of this study is to define the rate of pathologic complete response rate (pCR) in the affected breast after the preoperative administration of NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with stage IIB-IIIC breast cancer. Pathologic complete response (pCR) is defined according to Hankoop et al [41] as either: the absence of any histological evidence of invasive breast cancer cells in the tissue specimen removed from the breast or the presence of invasive tumor equal to or less than 10mm after preoperative treatment, determined at definitive breast surgery.</description>
          <population>Assessable tumors from study participants who had received at least one cycle of protocol therapy.</population>
          <units>percentage of tumors</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Tumors</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Tumors</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" lower_limit="25" upper_limit="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Definition of the Safety Profiles of Protocol Therapy</title>
        <description>Definition of the safety profiles of protocol therapy in study participants as shown by the number of study participants experiencing adverse events or other toxicity.</description>
        <time_frame>Up to 30 days Post-Last Dose of Protocol Therapy, About 7 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NOV-002 and Chemotherapy</title>
            <description>NOV-002:
Cycle 1, Day -1 only: 60 mg intravenously (IV) x 2, 3 hours (+/- 30 minutes) apart
Cycles 1 - 8, Day 1: 60 mg IV, 1 hour (+/- 30 minutes) prior to chemotherapy administration
Cycle 1 - 8, Days 2 - 21: 60 mg subcutaneous injections
Cyclophosphamide: 600 mg/m2 IV, Cycles 1 - 4, Day 1
Doxorubicin: 60 mg/m2 IV, Cycles 1 - 4, Day 1
Docetaxel: 100 mg/m2 IV, Cycles 5 - 8, Day 1
Cyclophosphamide
Docetaxel
Doxorubicin
NOV 002</description>
          </group>
        </group_list>
        <measure>
          <title>Definition of the Safety Profiles of Protocol Therapy</title>
          <description>Definition of the safety profiles of protocol therapy in study participants as shown by the number of study participants experiencing adverse events or other toxicity.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation Between Myeloid Derived Suppressor Cell (MDSC) Levels and Pathologic Complete Response (pCR) and Non-Responders</title>
        <description>The investigators hypothesized that patients with favorable responses, i.e. pCR, are more likely to have significantly lower levels of MDSCs than non-responders. MDSC levels will be measured at baseline and on day 1 of each treatment cycle, cycles 1 through 8.</description>
        <time_frame>Baseline, Day 1 of Cycles 1 through 8, about 7 months</time_frame>
        <population>Study participants who were evaluable for pathologic response.</population>
        <group_list>
          <group group_id="O1">
            <title>NOV-002 and Chemotherapy</title>
            <description>NOV-002:
Cycle 1, Day -1 only: 60 mg intravenously (IV) x 2, 3 hours (+/- 30 minutes) apart
Cycles 1 - 8, Day 1: 60 mg IV, 1 hour (+/- 30 minutes) prior to chemotherapy administration
Cycle 1 - 8, Days 2 - 21: 60 mg subcutaneous injections
Cyclophosphamide: 600 mg/m2 IV, Cycles 1 - 4, Day 1
Doxorubicin: 60 mg/m2 IV, Cycles 1 - 4, Day 1
Docetaxel: 100 mg/m2 IV, Cycles 5 - 8, Day 1
Cyclophosphamide
Docetaxel
Doxorubicin
NOV 002</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation Between Myeloid Derived Suppressor Cell (MDSC) Levels and Pathologic Complete Response (pCR) and Non-Responders</title>
          <description>The investigators hypothesized that patients with favorable responses, i.e. pCR, are more likely to have significantly lower levels of MDSCs than non-responders. MDSC levels will be measured at baseline and on day 1 of each treatment cycle, cycles 1 through 8.</description>
          <population>Study participants who were evaluable for pathologic response.</population>
          <units>MDSC/uL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline, non-pCR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="257.4" spread="0.001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline, pCR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.3" spread="0.001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycles 2-4 Day 1, non-pCR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="534.2" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycles 2-4 Day 1, pCR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="207.8" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycles 5-8 Day 1, non-pCR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="363.7" spread="0.006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycles 5-8 Day 1, pCR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171.5" spread="0.006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>NOV-002 and Chemotherapy</title>
          <description>NOV-002:
Cycle 1, Day -1 only: 60 mg intravenously (IV) x 2, 3 hours (+/- 30 minutes) apart
Cycles 1 - 8, Day 1: 60 mg IV, 1 hour (+/- 30 minutes) prior to chemotherapy administration
Cycle 1 - 8, Days 2 - 21: 60 mg subcutaneous injections
Cyclophosphamide: 600 mg/m2 IV, Cycles 1 - 4, Day 1
Doxorubicin: 60 mg/m2 IV, Cycles 1 - 4, Day 1
Docetaxel: 100 mg/m2 IV, Cycles 5 - 8, Day 1</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Femoral Artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Muscular Weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythroysaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sensory Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Consitpation</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sensory Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alberto Montero MD</name_or_title>
      <organization>UM/Sylvester Comprehensive Cancer Center</organization>
      <phone>305-243-3771</phone>
      <email>amontero2@med.miami.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

